RxDoctor Payments Data

James Pratty, MD

Psychiatry · Torrance, CANPI 1528049608

Payments from drug & device makers

$598,452in general payments, 2019–2025

Across 1,134 payments — averaging $527.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108K
  • Teva Pharmaceuticals USA, Inc.$99K
  • Alkermes, Inc.$54K
  • Sunovion Pharmaceuticals Inc.$51K
  • Vanda Pharmaceuticals Inc.$36K
  • plus $43K from 16 others

What the payments were for

  • Consulting fees$19,7033%
  • Speaking & faculty fees$503,05784%
  • Travel & lodging$53,2279%
  • Food & beverage$22,1114%
  • Education$3540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$598,452 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$204,876
Medicare patients
381
Services billed
2,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate207$509,956
AustedoDeutetrabenazine45$203,864
VraylarCariprazine Hcl140$193,935
IngrezzaValbenazine Tosylate11$113,001
AristadaAripiprazole Lauroxil27$73,558
CaplytaLumateperone Tosylate34$55,940
TrintellixVortioxetine Hydrobromide78$36,002
Olanzapine OdtOlanzapine147$13,806
Aripiprazole189$11,942
Lurasidone Hcl143$10,976
QuviviqDaridorexant Hcl17$7,886
Olanzapine556$5,651
Quetiapine Fumarate542$5,234
Clozapine94$4,309
Divalproex Sodium374$3,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,483$509,956207 claims
Teva Pharmaceuticals USA, Inc.Austedo$98,757$203,86445 claims
AbbVieVraylar$207,086$193,935140 claims
Neurocrine Biosciences, Inc.Ingrezza$29,885$113,00111 claims
Alkermes, Inc.Aristada$54,488$73,55827 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$107,780$55,94034 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$87$36,00278 claims
Idorsia Pharmaceuticals US IncQuviviq$1,190$7,88617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →